Government Agencies

This article highlights groundbreaking research on tuberculosis (TB) treatment, revealing why a key TB drug remains effective against resistant strains. Rutgers Health researchers uncover the molecular mechanisms that enable this drug to combat TB bacteria, potentially inspiring improved treatments and drug development strategies. The findings emphasize the need for continued research to address antibiotic resistance and enhance global TB control efforts.

This webpage highlights a recent study that reveals gaps in gonorrhea and chlamydia testing during pregnancy. It emphasizes the potential health risks these infections pose to both mother and child, urging the need for improved screening protocols. The study underscores the importance of regular prenatal testing to ensure better health outcomes for both.

This guideline outlines the importance of Medicaid 1115 waivers and pre-release healthcare coverage in improving access to hepatitis C (HCV) treatment for incarcerated individuals. It discusses how expanding Medicaid coverage can enhance continuity of care, reduce transmission, and support reentry populations.

This article highlights a new hepatitis C test that delivers rapid results without requiring a separate lab visit, improving access to early diagnosis and treatment. It emphasizes the importance of expanding testing efforts, particularly for high-risk populations, to support hepatitis C elimination. The article underscores the need for continued innovation in screening technologies to reduce barriers to care and prevent long-term health complications like liver disease and cancer.

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2024 edition of the report is, as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2024, 193 countries and areas with more than 99% of the world’s population and TB cases reported data.

This issue brief outlines a pharmacist's authority to initiate PrEP & PEP and participate in collaborative practice agreements.

This webinar recording discusses how to reduce disparities in hepatitis, research and community partnerships have been essential in reaching at-risk and underserved populations by addressing the adverse social determinants that are responsible for these disparities. For example, successful collaborations often simplify and facilitate access and linkage to care. In many cases, communities are considered as program recipients or research subjects instead of critical partners who should be significant contributors to the design and implementation of an initiative.

This fact sheet discusses the clinical summary of the USPSTF Recommendation for serologic screening for genital herpes infection.

This fact sheet discusses clinical summary of USPSTF recommendation screening for syphilis infection in nonpregnant adolescents and adults.

AHEAD is "one tool" supporting and/or tracking the Ending the HIV Epidemic in the U.S. (EHE). AHEAD helps track the six EHE indicators in areas with the highest burden of HIV. It complements and serves as one of many important implementation elements of the EHE initiative and the National HIV/AIDS Strategy. This interactive dashboard can be used to inform planning and is a starting place to explore other HIV data sources.